Lockheed Martin Corporation vs DENTSPLY SIRONA Inc — how do they compare? Lockheed Martin Corporation trades at $509.59 (market cap $117.22B), while DENTSPLY SIRONA Inc trades at $8.83 (market cap $1.73B). The key difference: Lockheed Martin Corporation is far larger — about 67.8× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals — on Pluang, investors hold Lockheed Martin Corporation for 86 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| LMT | XRAY | |
|---|---|---|
Market Cap | $117.22B | $1.73B |
Volume | 1,101,121 | 6,198,582 |
Sector | Industrials | Health |
52-Week High | $676.70 | $14.68 |
52-Week Low | $439.19 | $8.52 |
Typical Hold Time | 86 Days | 72 Days |
Enterprise Value | $133.96B | $3.80B |
Dividend Yield | 2.72% | 5.04% |
Signals from Pluang's Aura AI — not financial advice
Lockheed Martin (LMT) trades at $509.59, up 2.08% over the past day, with a bearish technical signal but strong analyst consensus. The company reported mixed quarterly earnings, missing in Q4 2025 and Q1 2026 but beating in Q2 2026, while revenue and cash flow trends show growth. Recent news highlights innovation in AI and autonomous systems, dividend increases, and ongoing defense contracts, supporting a positive long-term outlook despite near-term volatility.
LMT presents a compelling investment case with a consensus price target of $635.33, implying significant upside, backed by robust cash flows and a dominant defense market position. Risks include reliance on government spending, fixed-price contract volatility, and rising debt levels, but the stock's current valuation and dividend track record offer a margin of safety for patient investors.
DENTSPLY SIRONA (XRAY) trades at $8.83, down 3.4% with bearish technical signals. The stock faces fundamental challenges with negative net income margins (-14.99%) and declining revenue trends ($3.68B in 2025). Recent Q2 2026 earnings beat expectations but sales fell 4.1% amid ongoing turnaround efforts. The company maintains strong institutional interest despite hitting 52-week lows in September 2026.
XRAY presents a high-risk opportunity with Wall Street maintaining a cautious stance (37.5% buy rating). The consensus price target of $13.40 offers 52% upside potential, but investors face execution risks in the dental equipment turnaround, margin pressures, and competitive challenges. Near-term catalysts include management's presentation at the Baird Healthcare Conference in September 2026.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →